James L. Hoehn

Suggest Changes
Learn More
PURPOSE Patients with early-stage, hormone receptor-positive breast cancer have considerable residual risk for recurrence after completing 5 years of adjuvant tamoxifen. In May 2001, the National(More)
  • 1